Last-Resort drug made available for Tough-to-Treat melanoma

NCT ID NCT06063746

NO_LONGER_AVAILABLE Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program offers vidutolimod (CMP-001) to people with refractory melanoma who have run out of standard options. It is a compassionate use access, not a clinical trial, so it is only available when no other treatments are left. The goal is to provide a potential therapy for those with few choices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vidutolimod (CMP-001)

What this could lead to

If it works, this could offer a treatment option for people with melanoma that hasn't responded to other therapies.

What could go wrong

This is a compassionate use program, not a formal trial, so there is no controlled data on how well it works or its risks. It may not help everyone, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MELANOMA